Piramal Pharma Faces FDA Scrutiny: 6 Observations at Turbhe Facility

Piramal Pharma Ltd's Turbhe facility underwent a Good Manufacturing Practices (GMP) inspection by the US FDA, resulting in a Form-483 with six observations. The company emphasized that these observations focus on procedural improvements rather than data integrity issues. This inspection follows recent FDA scrutiny at other Piramal facilities, including Riverview, USA, which received three observations in early February. Despite these challenges, Piramal remains committed to maintaining high compliance standards and is preparing detailed responses to address the FDA's concerns. The company's proactive approach to regulatory compliance aims to ensure the quality and safety of its pharmaceutical products.
Sources: Fierce Pharma, Business Standard, Piramal Pharma Solutions website